Epidemiology and key clinical and therapeutic indicators of diabetes mellitus in Russian Federation according to the World Health Organization's strategy goals

BACKGROUND: Diabetes mellitus (DM) is a dangerous challenge to society and high-priority goals for health systems worldwide due to the severity of diabetic complications leading to disability and premature mortality in this category of patients.

AIM: To carry out an analysis of epidemiological, clinical and therapeutic characteristics of DM control in the Russian Federation (RF) according to the strategy goals of the World Health Organization (WHO) by 2030 (diagnosis of DM; control of glycemia, blood pressure in DM patients; assignment of statins to DM patients; ensuring the availability of insulin and means for self-monitoring of the level of glycemia) based on the «Database of clinical and epidemiological monitoring of DM in the territory of the Russian Federation (RF)».

MATERIALS AND METHODS. The research performed on the basis of the de-personalized "Database of clinical and epidemiological monitoring of DM in the territory of the RF", certificate of state registration database №2020622447 (http://diaregistry.ru, register of DM), which included 87 regions of the RF. Data are presented as cross-sectional study in 01.07.2024.

RESULTS: According to the Database of clinical and epidemiological monitoring of DM in the territory of the RF, the target HbA1c<7% is achieved in 29% of patients with type 1 DM (T1DM) and 42% of patients with T2DM. Effective blood pressure control in people with diagnosed DM is achieved in 84% of patients with T1DM and 60% of patients with T2DM. The proportion of patients receiving statins aged 40 and over is 14.1% for T1DM, 15.9% for T2DM. All patients with T1DM (100%) and T2DM on insulin therapy are provided with insulin under the program of state guarantee of drug provision, of them insulin analogues in T1DM — 84,8%, in T2DM — 60,9%, the rest — recombinant human insulins. Self-monitoring devices (glucometers and test strips for them) are provided to 100% of patients with DM. Since 2023, patients with T1DM under 18 years old are provided by continuous glucose monitoring systems.

CONCLUSION: Common diabetes monitoring system based on "Database of clinical and epidemiological monitoring of DM in the territory of the RF" at the national level allows to assess the effectiveness of programs to achieve the WHO targets. The data analysis identifies priority areas for the most effective and achievable interventions to strengthen and monitor diabetes control. Providing timely, reliable and sustainable national information on risk factors, epidemiology and clinical data of DM, access to medical drugs and modern technologies of control requires coordinated work by health professionals.

1. International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium; 2021 [cited 11.04.2023]. Available from: https://www.diabetesatlas.org

2. Vsemirnaya Organizatsiya Zdravookhraneniya. Sem’desyat pyataya sessiya Vsemirnoi assamblei zdravookhraneniya, Zheneva, 22–28 maya 2022 g. Rezolyutsii i resheniya. Prilozheniya. Zheneva, 2022 g. Available from: https://apps.who.int/gb/ebwha/pdf_files/WHA75-REC1/A75_REC1_Interactive_ru.pdf]

3. Dedov II, Shestakova MV, Vikulova OK, et al. Atlas of the diabetes register of the Russian Federation. Status 2018. Diabetes Mellitus. 2019;22(2S):4−61. (In Russ.)]. doi: https://doi.org/10.14341/DM12208

4. Federal’naja sluzhba gosudarstvennoj statistiki. Zdravoohranenie v Rossii 2021 g. (In Russ.) Available from: https://rosstat.gov.ru/folder/210/document/13218]

5. Deev IA, Kobyakova OS, Starodubov VI, et al. Zabolevaemost’ vsego naseleniya Rossii v 2023 godu: statisticheskie materialy. — Moscow: FGBU «TsNIIOIZ» Minzdrava Rossii; 2024. (In Russ.). doi: https://doi.org/10.21045/978-5-94116-160-7-2024

6. Dedov I.I. Sakharnyy diabet v Rossiyskoy Federatsii: problemy i puti resheniya. Diabetes mellitus. 1998;1(1):7-18. (In Russ.) doi: https://doi.org/10.14341/2072-0351-6209

7. Dedov II, Shestakova MV, Vikulova OK. National register of diabetes mellitus in Russian Federation: status on 2014. Diabetes mellitus. 2015;18(3):5-23. (In Russ.)]. doi: https://doi.org/10.14341/DM201535-22

8. Dedov II, Shestakova MV, Vikulova OK. Epidemiology of diabetes mellitus in Russian Federation: clinical and statistical report according to the federal diabetes registry. Diabetes mellitus. 2017;20(1):13-41. (In Russ.)]. doi: https://doi.org/10.14341/DM8664

9. Dedov II, Shestakova MV, Vikulova OK, et.al. Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of hypoglycaemic therapy according to the Federal Diabetes Register, status 2017. Diabetes Mellitus. 2018;21(3):144-159. (In Russ.)]. doi: https://doi.org/10.14341/DM9686

10. Shestakova MV, Vikulova OK, Zheleznyakova AV, et al. Diabetes epidemiology in Russia: what has changed over the decade? Therapeutic Archive. 2019;91(10):4–13. (In Russ.)]. doi: https://doi.org/10.26442/00403660.2019.10.000364

11. Dedov II, Shestakova MV, Peterkova VA, et al. Diabetes mellitus in children and adolescents according to the Federal diabetes registry in the Russian Federation: dynamics of major epidemiological characteristics for 2013–2016. Diabetes mellitus. 2017;20(6):392-402. (In Russ.)]. doi: https://doi.org/10.14341/DM9460

12. Dedov II, Shestakova MV, Vikulova OK, et al. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes mellitus. 2021;24(3):204-221. (In Russ.)]. doi: https://doi.org/10.14341/DM12759

13. Dedov II, Shestakova MV, Mayorov AY, et al. Diabetes mellitus type 1 in adults. Diabetes mellitus. 2020;23(1S):42-114. (In Russ.)] doi: https://doi.org/10.14341/DM12505

14. Dedov II, Shestakova MV, Mayorov AY, et al. Diabetes mellitus type 2 in adults. Diabetes mellitus. 2020;23(2S):4-102. (In Russ.)] doi: https://doi.org/10.14341/DM12507

15. Peterkova VA, Shestakova MV, Bezlepkina OB, et al. Diabetes mellitus type 1 in childhood. Diabetes mellitus. 2020;23(1S):4-40. (In Russ.)] doi: https://doi.org/10.14341/DM12504

16. Rossiiskaya assotsiatsiya endokrinologov. Klinicheskie rekomendatsii. Sakharnyi diabet 2 tipa u detei, 2022 god. Available from: https://cr.minzdrav.gov.ru/preview-cr/622_5]

17. Dedov II, Shestakova MV, Galstyan GR. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes mellitus. 2016;19(2):104-112. (In Russ.)] doi: https://doi.org/10.14341/DM2004116-17

18. Kobalava ZD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.)] doi: https://doi.org/10.15829/1560-4071-2020-3-3786

19. Dedov II, Shestakova MV, Vikulova OK, et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Diabetes mellitus. 2023;26(2):104-123.] doi: https://doi.org/10.14341/DM13035

20. Shestakova EA, Lunina EY, Galstyan GR, et al. Type 2 diabetes and prediabetes prevalence in patients with different risk factor combinations in the NATION study. Diabetes Mellitus. 2020;23(1):4-11. (In Russ.)] doi: https://doi.org/10.14341/DM12286

21. GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 [published correction appears in Lancet. 2023 Sep 30;402(10408):1132. doi: https://doi.org/10.1016/S0140-6736(23)02044-5]. Lancet. 2023;402(10397):203-234. doi: https://doi.org/10.1016/S0140-6736(23)01301-6

22. Green A, Hede SM, Patterson CC, et al. Type 1 diabetes in 2017: global estimates of incident and prevalent cases in children and adults. Diabetologia. 2021;64(12):2741-2750. doi: https://doi.org/10.1007/s00125-021-05571-8

23. Xu G, Liu B, Sun Y, et al. Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: population based study. BMJ. 2018 Sep 4;362:k1497. doi: https://doi.org/10.1136/bmj.k1497

24. National Diabetes Statistics Report [Internet]. Centers for Disease Control and Prevention [cited 2025 Jan 10]. Available from: https://www.cdc.gov/diabetes/php/data-research/index.html

25. Xie J, Wang M, Long Z, et al. Global burden of type 2 diabetes in adolescents and young adults, 1990-2019: systematic analysis of the Global Burden of Disease Study 2019. BMJ. 2022;379:e072385. doi: https://doi.org/10.1136/bmj-2022-072385

26. Collins VR, Dowse GK, Toelupe PM, et al. Increasing prevalence of NIDDM in the Pacific island population of Western Samoa over a 13-year period. Diabetes Care. 1994;17(4):288-296. doi: https://doi.org/10.2337/diacare.17.4.288

27. Wang L, Peng W, Zhao Z, et al. Prevalence and Treatment of Diabetes in China, 2013-2018 [published correction appears in JAMA. 2022 Mar 15;327(11):1093. doi: 10.1001/jama.2022.2814]. JAMA. 2021;326(24):2498-2506. doi: https://doi.org/10.1001/jama.2021.22208

28. Drapkina OM, Kontsevaya AV, Kalinina AM, et al. 2022 Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines. Cardiovascular Therapy and Prevention. 2022;21(4):3235. (In Russ.)] doi: https://doi.org/10.15829/1728-8800-2022-3235

29. Dedov II, Shestakova MV, Mayorov AY, et al. Standards of specialized diabetes care. Diabetes Mellitus. 2021;24(S1):1-235 (In Russ.)]. doi: https://doi.org/10.14341/DM12802

30. National Diabetes Audit 2021-22, Report 1: Care Processes and Treatment Targets, Detailed Analysis Report [Internet]. NHS England. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/report-1-care-processes-and-treatment-targets-2021-22-full-report/cp-and-tt-1718-2122

31. Morris DH, Khunti K, Achana F, et al. Progression rates from HbA1c 6.0-6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis. Diabetologia. 2013;56(7):1489-93. doi: https://doi.org/10.1007/s00125-013-2902-4

32. Droumaguet C, Balkau B, Simon D, et al. Use of HbA1c in predicting progression to diabetes in French men and women: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care. 2006;29(7):1619-25. doi: https://doi.org/10.2337/dc05-2525

33. Pradhan AD, Rifai N, Buring JE, Ridker PM. Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. Am J Med. 2007;120(8):720-7. doi: https://doi.org/10.1016/j.amjmed.2007.03.022

34. Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362(9):800-11. doi: https://doi.org/10.1056/NEJMoa0908359

35. Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986. doi: https://doi.org/10.1056/NEJM199309303291401

36. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653. doi: https://doi.org/10.1056/NEJMoa052187

37. Zheleznyakova AV, Vikulova OK, Serkov AA, et al. Dynamic monitoring of cardiovascular diseases in patients with diabetes mellitus according to mobile medical center (Diamodule) in the regions of Russia. Consilium Medicum. 2020;22(10):39–44. (In Russ.)] doi: https://doi.org/10.26442/20751753.2020.10.200323

38. Balanova YA, Shalnova SA, Imaeva AE, et al. Prevalence, Awareness, Treatment and Control of Hypertension in Russian Federation (Data of Observational ESSE-RF-2 Study). Rational Pharmacotherapy in Cardiology. 2019;15(4):450-466. (In Russ.)] doi: https://doi.org/10.20996/1819-6446-2019-15-4-450-466

39. Balanova JA, Shalnova SA, Kutsenko VA, et al. Population aspects of arterial hypertension therapy. Focus on fixed combinations. Arterial Hypertension. 2022;28(5):482-491. (In Russ.)] doi: https://doi.org/10.18705/1607-419X-2022-28-5-482-491

40. Mach F, Baigent C, Catapano AL, и др. 2019 Рекомендации ESC/EAS по лечению дислипидемий: модификация липидов для снижения сердечно-сосудистого риска // Российский кардиологический журнал. — 2020. — Т.25. — №5. — С.3826. [Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk. Russian Journal of Cardiology. 2020;25(5):3826. (In Russ.)] doi: https://doi.org/10.15829/1560-4071-2020-3826

41. Shalnova SA, Deev AD, Metelskaya VA, et al. Awareness and treatment specifics of statin therapy in persons with various cardiovasular risk: the study ESSE-RF. Cardiovascular Therapy and Prevention. 2016;15(4):29-37. (In Russ.)] doi: https://doi.org/10.15829/1728-8800-2016-4-29-37

42. Maiorino MI, Signoriello S, Maio A, et al. Effects of Continuous Glucose Monitoring on Metrics of Glycemic Control in Diabetes: A Systematic Review With Meta-analysis of Randomized Controlled Trials. Diabetes Care. 2020;43(5):1146-1156. doi: https://doi.org/10.2337/dc19-1459